PRINCETON, N.J. / Dec 20, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City on Thursday, January 4, 2024. Adam Lenkowsky, executive vice president, chief commercialization officer, will answer questions about the company during a fireside chat at 11 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$57.33 |
| Daily Change: | 1.03 1.83 |
| Daily Volume: | 39,505,640 |
| Market Cap: | US$116.380B |
December 09, 2024 November 19, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
